Wed. 6 Mar 2024, 2:35am ET
Benzinga
News
The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $250.0 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering to be sold by BridgeBio.
The offering is expected to close on or about March 8, 2024, subject to the satisfaction of customary closing conditions